We purified human plasma lysophospholipase D that produces physiologically active lysophosphatidic acid (LPA) and showed that it is a soluble form of autotaxin, an ecto-nucleotide pyrophosphatase/phosphodiesterase, originally found as a tumor cell motility-stimulating factor. Its lower Km value for a lysophosphatidylcholine than that for a synthetic substrate of nucleotide suggest that lysophosphatidylcholine is a more likely physiological substrate for autotaxin, and that its predicted physiological and pathophysiological functions could be mediated by its activity to produce LPA, an intercellular mediator.
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SUMMARY
We purified human plasma lysophospholipase D that produces physiologically active lysophosphatidic acid (LPA) and showed that it is a soluble form of autotaxin, an ecto-nucleotide pyrophosphatase/phosphodiesterase, originally found as a tumor cell motility-stimulating factor. Its lower Km value for a lysophosphatidylcholine than that for a synthetic substrate of nucleotide suggest that lysophosphatidylcholine is a more likely physiological substrate for autotaxin, and that its predicted physiological and pathophysiological functions could be mediated by its activity to produce LPA, an intercellular mediator.
Recombinant autotaxin was found to have lysophospholipase D activity; its substrate specificity and metal ion requirement were the same as those of the purified plasma enzyme. The activity of lysophospholipase D for exogenous lysophosphatidylcholine in human serum was found to increase in normal pregnant women at the third trimester of pregnancy and to a higher extent in patients in threatened preterm delivery, suggesting its roles in induction of parturition. Particularly, lysophosphatidic acid (LPA 1 , radyl-sn-glycerol-3-phosphate) has received interest because of its identification as an active component in platelet-aggregating activity and vasoactivity in incubated animal sera and plasma (4) . Later, its principle effects were found to be growth-related; on cellular proliferation, alterations in differentiation and suppression of apoptosis (2) (3) (4) (5) . Other important effects are its cytoskeletal response; cell aggregation, contraction, adhesion or chemotaxis (1) (2) (3) (4) (5) . Its diverse activities appear to be regulated by the relative distribution of its specific receptors in a family of endothelial differentiation genes (Edg), desensitization of the receptors and the local concentration of LPA determined by balance between LPA-producing and -degrading enzyme activities (1) (2) (3) (4) (5) (6) . Although LPA is produced intracellularly in phospholipid biosynthesis and turnover, this should be differentiated from its actual pool as a first messenger unless there are efficient mechanisms for its release into extracellular fluid or leaflets of plasma membranes (3) (4) (5) (6) . In this sense, secretory or ecto-type LPA-producing enzymes can supply LPA directly to its receptors.
The first study on extracellular production of LPA was our own, detecting lysophospholipase D (lysoPLD) activity that produces 4 bioactive LPA from lysophosphatidylcholine (LPC) in rat plasma (7) . Its distinct substrate specificity and cation-requirement from known intracellular lysoPLD activity suggested that it is a hitherto-uncharacterized metallo-enzyme (7) (8) (9) . To understand its physiological and pathological significance, the identity of lysoPLD activity in blood circulation should be clarified.
Therefore we purified and characterized lysoPLD in human plasma, and obtained strong evidence that it is a soluble form of autotaxin (ATX), a member of the ecto-nucleotide pyrophosphatase/phosphodiesterase (PDE) family (10) . Identification of purified lysoPLD -Fractions with lysoPLD activity in the final purification step by the second anion exchange chromatography were combined and subjected to SDS-PAGE on 7.5% gel. After staining the gel with SyproRuby, the 110 kDa band was cut and treated with trypsin. The tryptic digest was directly analyzed by nanoscale high-performance liquid chromatography on a C18 column (0.1 x 50 mm) coupled to tandem mass spectrometer (Q-Tof2) equipped with a nanoelectrospray ionization source. Positive ion tandem mass spectra were measured. The amino acid sequence from the N-terminus of the purified enzyme was determined in a protein sequencer (Procise cLC).
EXPERIMENTAL PROCEDURES
Phospholipids
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Assay for lysoPLD and nucleotide PDE activities -LysoPLD activity was estimated by determining choline liberated from exogenously added LPC, PC or GPC. In the standard assay, diluted sample solutions (0.1 ml) were first incubated with 0.05 ml of the substrate dispersion in saline containing 0.05 % fatty acidfree bovine serum albumin at 37 o C for various time intervals up to 24 h. Choline in 0.1-ml aliquots of the incubation mixture was oxidized to betaine with 1 U/ml choline oxidase (12) , and hydrogen peroxide concomitantly generated was determined by fluorometry (13) . In brief, the second assay mixture consisted of 0.1 ml of the first assay mixture, 2. were provided by Dr. J. Aoki, the University of Tokyo, Japan, who constructed rat cDNA for ATX by reverse transcription-polymerase chain reaction using rat liver cDNA library as template DNA.
Human cDNA for ATX-t amplified from human liver DNA library was kindly provided by Dr. T. Katada, the University of Tokyo, and was transfected in CHO-K1 cells, as described for rat ATX. Both its lysoPLD and nucleotide PDE activities were measured as described above.
RESULTS
Re-solubilized proteins from human plasma precipitated with between 30-60% ammonium sulfate were fractionated by sequential HPLC. A summary of results on purification of lysoPLD is presented in Table I . We obtained 14,478-fold purified lysoPLD with 6.1 % recovery at the seventh purification step (Phenyl-9 5PW). By the second anion exchange chromatography, the lysoPLD was further highly-purified with 1.2 % yield; a major peak with lysoPLD activity was separated by a minor peak with the enzyme activity ( Fig. 1) . The first major peak (fractions 47-51) showed a single band at 110 kDa stained with silver on SDS-PAGE under non-reducing conditions (Fig. 2) . This is in agreement with the estimated 110 kDa for a protein peak with lysoPLD activity by its and Met 325 in that of ATX-t or PD-I (18). Thus, our present result showed that human plasma lysoPLD is a soluble form of human ATX-t or PD-I , but not ATX-m. Consistent with this suggestion, the elution pattern in the second anion exchange chromatography of human plasma lysoPLD was found to be similar with that of nucleotide PDE activity (Fig. 1) . The COOH-terminus of purified lysoPLD was identified as the isoleucine residue, since the peptide from Thr 854 to Ile 863 corresponds to the Cterminal region of ATX-t (Fig. 3 ). In addition, the N-terminal sequences of the 110 kDa band were determined as AEGWEEGPPTVLSD and RLHTKGSTEERHLLY, which were identical to the sequences of (Fig. 5-B) . Taken altogether, the current results indicate that human plasma lysoPLD is a soluble form of human ATX-t.
An early investigation showed that several fractions with nucleotide PDE activity were separated by electrophoresis of human serum, one of which had a much higher Km value (30 mM) for pNP-TMP than those suggested for others (less than 0.3 mM) and increased during pregnancy (23) . In our preliminary work, serum lysoPLD activity measured with a radioactive 16:0-LPC was found to increase in humans in pregnancy (24) . In this study with a 14 more convenient lysoPLD assay, we confirmed our previous finding and found that the elevated activity decreased to near the level of non-pregnant women after delivery (Fig. 6) . Interestingly, its activity in serum from patients with threatened preterm delivery at the third trimester of pregnancy was significantly higher than that of normal pregnant women (Fig. 6) . These results suggest that lysoPLD-mediated production of LPA plays physiological roles in parturition, since LPA injected intravenously into rats was reported to increase intrauterine pressure due to contraction of uterine smooth muscle in vivo (25) .
DISCUSSION
In the current study, by LC-MS/MS, we found that the amino acid sequences of trypsin-digested peptides from purified human plasma lysoPLD were fitted to those of human ATX-t and PD- (Table I) Activity (nmol/ml) Activity (nmol/ml) Activity (nmol/ml) Activity (nmol/ml) T 
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